Chronic treatment with citalopram does not affect the expression of α1-adrenergic receptor (α1-AR) subtypes

Polish Journal of Pharmacology

Volumn 56, Issue 6, 2004, Pages 831-836

  Kreiner, Grzegorz ^a   Bielawski, Adam ^a   Zelek Molik, Agnieszka ^a   Kowalska, Marta ^a   Nalepa, Irena ^a  

^a POLISH ACADEMY OF SCIENCES   (Poland)

Author keywords

3H prazosin binding; Brain cortex; Citalopram; mRNA expression; Rat

Indexed keywords

ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; CITALOPRAM; MESSENGER RNA; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN TISSUE; CONTROLLED STUDY; DRUG MECHANISM; LONG TERM CARE; MALE; NONHUMAN; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RAT; RAT STRAIN; RECEPTOR BINDING; RECEPTOR DENSITY; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; CITALOPRAM; GENE EXPRESSION REGULATION; MALE; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA-1; RNA, MESSENGER; SEROTONIN UPTAKE INHIBITORS;

EID: 14244264309     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. 1-adrenergic receptor subtypes in discrete regions of rat brain. J Neurosci, 1990, 10, 2580-2586.
2. Chomczynski P: A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques, 1993, 15, 532-537.
3. Duhl DM, Gillespie DD, Sulser F: Ethidium bromide fluorescence of 28S ribosomal RNA can be used to normalize samples in Northern or dot blots when analyzing small drug-induced changes in specific mRNA. J Neurosci Methods, 1992, 42, 211-218.
4. 2+ in smooth muscle. Nature, 1987, 329, 333-335.
5. 1B-adrenoceptor mRNA using competitive RT-PCR. Pol J Pharmacol, 2002, 54, 401-405.
6. 1-adrenoceptors in the rat cortex. Eur J Pharmacol, 1985, 119, 113-116.
7. Milne RJ, Goa KL: Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs, 1991, 41, 450-477.
8. 2+. Pharmacol Rev, 1988, 40, 87-119.
9. Nalepa I: The effect of psychotropic drugs on the interaction of protein kinase C with second messenger systems in the rat cerebral cortex. Pol J Pharmacol, 1994, 46, 1-14.
10. 1A-adrenoceptor mRNA level in rat prefrontal cortex. Eur J Pharmacol, 2002, 444, 151-159.
11. Nalepa I, Manier HD, Gillespie DD, Rossby SP, Schmidt DE, Sulser F: Lack of β-adrenoceptor desensitization in brain following the dual noradrenaline and serotonin reuptake inhibitor venlafaxine. Eur Neuropsychopharmacol, 1998, 8, 227-232.
12. Nalepa I, Sulser F: New hypotheses to guide future antidepressant drug development. In: Antidepressants: Past, Present and Future. Handbook of Experimental Pharmacology, vol. 157. Ed. Preskorn SH, Feighner JP, Stanga CY, Ross R, Springer-Verlag, Berlin, Heidelberg, New York, 2004, 519-563.
13. Nalepa I, Vetulani J: Different mechanisms of β-adrenoceptor downregulation by chronic imipramine and electroconvulsive treatment: possible role for protein kinase C. J Neurochem, 1991, 57, 904-910.
14. Nalepa I, Vetulani J: Enhancement of the responsiveness of cortical adrenergic receptors by chronic administration of the 5-hydroxytryptamine uptake inhibitor citalopram. J Neurochem, 1993, 60, 2029-2035.
15. Nalepa I, Vetulani J: The responsiveness of cerebral cortical adrenergic receptors after chronic administration of atypical antidepressant mianserin. J Psychiatry Neurosci, 1994, 19, 120-128.
16. 1-adrenoceptors following destruction of noradrenergic or serotoninergic nerve terminals. Pol J Pharmacol, 1988, 40, 393-400.
17. 1c. J Biol Chem, 1996, 271, 5839-5843.
18. 3H]prazosin binding sites in the rat. Brain Res, 1984, 310, 360-362.
19. Vetulani J, Nalepa I: Antidepressants: past, presence and future. Eur J Pharmacol, 2000, 405, 351-363.
20. 1D-adrenoceptor protein detectable in rat tissues? Naunyn-Schmiedebergs Arch Pharmacol, 1997, 355, 438-446.
21. 1-Adrenoceptor subtypes. Eur J Pharmacol, 1999, 375, 261-276.